Viking Global Investors
ABCL icon

Viking Global Investors’s AbCellera Biologics ABCL Stock Holding History

Viking Global Investors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-19,083,744
Closed -$648M – 89
2021
Q1 		$648M Sell
19,083,744
-200,000
-1% -$7.97M 1.93% 19
2020
Q4 		$776M Buy
+19,283,744
New +$882M 2.13% 12

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors's ABCL Position: Q2 2021 in Review

Viking Global Investors sold out of AbCellera Biologics (ABCL) in Q2 2021, closing a stake of 19,083,744 shares — an estimated $648M sold.

Viking Global Investors first reported a position in ABCL in Q4 2020 and held it in 2 quarters. The position peaked at $776M in Q4 2020. 114 funds tracked by Wall St. Rank hold ABCL as of Q2 2021.

  • Viking Global Investors reported no remaining AbCellera Biologics position as of Q2 2021 after selling out during the quarter.
  • Viking Global Investors sold 19,083,744 AbCellera Biologics shares in Q2 2021, an estimated $648M.
  • Viking Global Investors first reported a position in AbCellera Biologics in Q4 2020 and held it in 2 quarters.
  • Viking Global Investors's AbCellera Biologics position peaked at $776M in Q4 2020.
  • 114 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2021.

Based on Viking Global Investors's 13F filing for Q2 2021, filed 16 Aug 2021.